Influence of Oscillating Packing Instrument on Microhardness of Bulk-Fill Composite: In Vitro Study

AIM: This study aimed to assess Vickers microhardness of Tetric EvoCeram Bulk Fill composite that was packed manually and using oscillating packing device. MATERIALS AND METHODS: Two different packing techniques were applied on Tetric EvoCeram Bulk Fill composite. For each packing technique, ten specimens (6 mm in diameter and 4 mm height) were prepared using a black-shaded Teflon mold. The resin was inserted in a bulk increment either packed manually or using Compothixo oscillating device and then light-cured for 40 s. Microhardness was analyzed at the top and the bottom surfaces. RESULTS: Overall, for both packing techniques, microhardness decreased significantly with the increase of depth. Tetric EvoCeram Bulk Fill composite when packed either manually or using oscillating device, did not show significant difference neither at the top surfaces of both applied techniques nor at the bottom surfaces of both applied techniques. CONCLUSION: Different packing techniques did not influence the microhardness of Tetric EvoCeram Bulk Fill composite. &nbsp

Biochemical and Genetical Evaluation of Pomegranate Impact on Diabetes Mellitus Induced by Alloxan in Female Rats

Abstract: Various food industries explored the possibility of developing a nutritional supplement rich in natural antioxidants from pomegranates. This study has focused on the ability of pomegranate peel and juice to study the antioxidant status. Thirty two rats were allocated in 4 groups as follows: GroupI; control group without any treatment; GroupII: diabetic animals injected with alloxan; Group III: diabetic peel group animals injected with alloxan and then feed on peel pomegranate; GroupIV: diabetic juice group animals injected with alloxan and then gavage with pomegranate juice. After 4 weeks of treatment biochemical analysis were measured such as glucose, insulin, alpha-amylase, lipid profile (cholesterol, triglyceride HDL, LDL and total lipids), total protein, homocysteine, total antioxidant capacity and liver enzymes (AST&ALT). In addition, pancreas and liver tissues were separated for genetic analysis in which pancreatic tissues were used for RAPD-PCR analysis and liver tissues for DNA fragmentation assay. Results showed significant increase in glucose and alpha amylase levels in diabetic group, while insulin decreased. Peel and juice of pomegranate ameliorates this effect and decreased glucose, alpha amylase while insulin level increased. Cholesterol, triglycerides, LDL and total lipids increased while HDL decreased in diabetic group. Peel and juice of pomegranate prevented these changes. The more pronounced effect appeared in group III treated with peel pomegranate. Total protein was not affected by alloxan or pomegranate. Homocysteine was significantly increased while total antioxidant capacity decreased in diabetic group. After treatment by pomegranate peel and juice, these parameters become near to the control values. AST and ALT were significantly increased in diabetic group. But after treatment with peel and juice, AST and ALT levels decreased and become near to the control level especially ALT value. Furthermore, rate of DNA fragmentation and DNA band polymorphism increased significantly in diabetic group. While after treatment by peel and juice rate of DNA band polymorphism and DNA fragmentation were decreased significantly. Pomegranate peel and juice showed significant reduction in LDL oxidative susceptibility and an increase in total antioxidant status. Pomegranate is able to reduce the progression in atherosclerosis. The antioxidant content in foods decreased the oxidative stress related diseases

Grafting Improves Fruit Yield of Cucumber Plants Grown under Combined Heat and Soil Salinity Stresses

[EN] Improving the productivity of cucumber (Cucumis sativus L.) plants subjected to combined salinity and heat stresses is a significant challenge, particularly in arid and semi-arid regions. Gianco F1 cucumbers were grafted onto five cucurbit rootstocks and, together with an ungrafted control, were grown in Egypt in a net house with saline soil during the summer season over two years. The vegetative growth, yield, quality, biochemical, and mineral composition traits were measured. Although many differences were observed among treatments, in general, the grafted plants had a performance better than or similar to that of the ungrafted plants, based on the different parameters measured. In particular, the cucumber plants grafted onto the Cucurbita maxima x C. moschata interspecific hybrid rootstocks VSS-61 F1 and Ferro had the highest early and total marketable yields. These two rootstocks consistently conferred higher vigor to the scion, which had lower flower abortion rates and higher chlorophyll contents. The fruit quality and N, P, and K composition in the leaves suffered few relevant changes as compared with the control. However, the leaves of the VSS-61 F1 had higher catalase activity, as well as proline and Se contents, while those of Ferro had higher Si content. This study reveals that the grafting of cucumber plants onto suitable rootstocks may mitigate the adverse effects caused by the combination of saline soil and heat stresses. This represents a significant improvement for cucumber cultivation in saline soil under high-temperature stress conditions in arid regions.Bayoumi, Y.; Abd-Alkarim, E.; El-Ramady, H.; El-Aidy, F.; Hamed, E.; Taha, N.; Prohens Tomás, J.... (2021). Grafting Improves Fruit Yield of Cucumber Plants Grown under Combined Heat and Soil Salinity Stresses. Horticulturae. 7(3):1-14. https://doi.org/10.3390/horticulturae70300611147

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. US National Institutes of Health and Operation Warp Spee